



Press release
March 25, 2020
Gothenburg

XVIVO Perfusion advances the date for submission of the January-March 2020 interim report

In order to provide information on XVIVO Perfusion's results and financial position for the period January-March 2020 as soon as possible, the company has decided to advance the submission of the report. New report date is Thursday 9 April at 7.30 a.m. A conference call will be held on Thursday, April 9 at 11.30 a.m.

March 25, 2020
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact
Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 21 50, magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB (publ) is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

This information is information that XVIVO Perfusion AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on March 25, 2020 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.